<DOC>
	<DOCNO>NCT01023737</DOCNO>
	<brief_summary>This study open label non randomize study hydroxychloroquine ( HCQ ) histone deacetylase ( HDAC ) inhibitor Vorinostat patient advance solid tumor determine maximum tolerate dose ( MTD ) evaluate safety antitumor activity drug combination .</brief_summary>
	<brief_title>Hydroxychloroquine + Vorinostat Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Hydroxychloroquine</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<criteria>Patients must least 16 year age Patients must histologically confirm nonhematological malignancy . Patients must receive failed standard treatment malignancy ; patient standard treatment available also eligible . Patients must ECOG PS 0 , 1 , 2 Patients must adequate hematologic , renal liver function ( i.e . absolute Neutrophil count &gt; 1000/mm3 , platelet &gt; 75,000/mm3 ) ; creatinine 2 time upper limit normal ( ULN ) total bilirubin ≤ 1.5 mg/dl , ALT AST £ 3 time upper limit institutional norm ALT , AST &lt; 5 time upper limit normal patient hepatic involvement . Patients must able provide write informed consent . Patients potential pregnancy impregnate partner must agree follow acceptable birth control method avoid conception . Women childbearing potential must negative pregnancy test . The antiproliferative activity experimental drug may harmful develop fetus nursing infant . Complete supportive palliative care continue provide ameliorate sign symptom preexist may arise study interfere objective study . Tumor block available previous surgery/biopsy . At tumor specific expansion , patient metastatic colorectal renal cell cancer enrol . Patients metastatic colorectal renal cancer must treat progressed intolerant standard care therapy . Patients colorectal cancer must treat past Irinotecan and/or Oxaliplatin and/or AvastinIEGFR therapy intolerant agent . No 4 line therapy permit metastatic setting . Patients colorectal cancer may enroll irrespective KRas mutational status , although document . Patients renal cell cancer must treat VEGF target therapy and/or mTOR inhibitor . No 4 line therapy permit metastatic setting . Prior treatment Vorinostat HCQ permit tumor type . Patients uncontrolled brain metastasis . Due risk disease exacerbation patient porphyria eligible . Due risk disease exacerbation patient psoriasis ineligible unless disease well control care specialist disorder agree monitor patient exacerbation . Patients previously document macular degeneration diabetic retinopathy . Patients chemotherapy radiotherapy within 2 week ( 6 week Nitrosoureas Mitomycin C ) prior enter study recover adverse event ≤ grade 1 due agent administer 4 week earlier . For targeted therapy patient need clear 5 half life . Patients may receive investigational agent . Patients take valproic acid another histone deacetylase inhibitor least 2 week prior enrollment . History allergic reaction attribute compound similar chemical biologic composition vorinostat HCQ . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . Major surgery significant traumatic injury occur within 21 day prior treatment . Clinically significant hypercalcemia ( include vomiting , dehydration neurological symptom ) . QTc &gt; 500 m baseline ( average 3 determination 10 minute interval ) . Gastrointestinal tract disease result inability take oral medication requirement IV alimentation , prior surgical procedure affect absorption , active peptic ulcer disease . Patients NJ , J G tube allow participate . Pregnant woman exclude study SAHA potential teratogenic abortifacient effect Patients know hepatitis B C HIV infection .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Malignant Solid Tumor</keyword>
	<keyword>Solid Tumor</keyword>
	<keyword>Hydroxychloroquine</keyword>
	<keyword>Vorinostat</keyword>
</DOC>